Novo Nordisk shares rise despite lowered full-year outlook
First-quarter sales and profit beat Full-year outlook lowered US competition from copycat drugs Danish drug maker Novo Nordisk (NOVO-B:CPH) was up 5% despite cutting its full-year outlook and missing first-quarter sales estimates...
07 May 2025